Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer

Abstract

A method is provided in various embodiments for determining a profile data set for a subject with prostate cancer or conditions related to prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-4. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

1 . A method for evaluating the presence of prostate cancer in a subject based on a sample from the subject, the sample providing a source of RNAs, comprising:
 a) determining a quantitative measure of the amount of at least one constituent of any constituent of any one table selected from the group consisting of Tables 1, 2, 3, and 4 as a distinct RNA constituent in the subject sample subject sample, wherein such measure is obtained under measurement conditions that are substantially repeatable and the constituent is selected so that measurement of the constituent distinguishes between a normal subject and a prostate cancer-diagnosed subject in a reference population with at least 75% accuracy; and   b) comparing the quantitative measure of the constituent in the subject sample to a reference value.   
     
     
         2 . A method for assessing or monitoring the response to therapy in a subject having prostate cancer based on a sample from the subject, the sample providing a source of RNAs, comprising:
 a) determining a quantitative measure of the amount of at least one constituent of any constituent of Tables 1, 2, 3, and 4 as a distinct RNA constituent, wherein such measure is obtained under measurement conditions that are substantially repeatable to produce subject data set; and   b) comparing the subject data set to a baseline data set.   
     
     
         3 . A method for monitoring the progression of prostate cancer in a subject, based on a sample from the subject, the sample providing a source of RNAs, comprising:
 a) determining a quantitative measure of the amount of at least one constituent of any constituent of Tables 1, 2, 3, and 4 as a distinct RNA constituent in a sample obtained at a first period of time, wherein such measure is obtained under measurement conditions that are substantially repeatable to produce a first subject data set;   b) determining a quantitative measure of the amount of at least one constituent of any constituent of Tables 1, 2, 3, and 4 as a distinct RNA constituent in a sample obtained at a second period of time, wherein such measure is obtained under measurement conditions that are substantially repeatable to produce a second subject data set; and   c) comparing the first subject data set and the second subject data set.   
     
     
         4 . A method for determining a prostate cancer profile based on a sample from a subject known to have prostate cancer, the sample providing a source of RNAs, the method comprising:
 a) using amplification for measuring the amount of RNA in a panel of constituents including at least 1 constituent from Tables 1, 2, 3, and 4 and   b) arriving at a measure of each constituent,   wherein the profile data set comprises the measure of each constituent of the panel and wherein amplification is performed under measurement conditions that are substantially repeatable.   
     
     
         5 . The method of  claim 1 , wherein said constituent is selected from
 a) Table 1 and is selected from:
 i) EGR1, POV1, CTNNA1, NCOA4, HSPA1A, CD44, ACPP, MEIS1, MUC1, STAT3, EPAS1, G6PD, CDH1, SVIL, TP53, PYCARD, or BCAM; 
 ii) EGR1, MEIS1, PLAU, CDH1, SERPINE1, or CTNNA1; or 
 iii) EGR1, CTNNA1, NCOA4, MEIS1, POV1, G6PD, SERPINE1, or CDH1; 
   b) Table 2 and is selected from:
 i) EGR1, CASP1, SERPINA1, ICAM1, NFKB1, ALOX5, HSPA1A, IFI16, ELA2, PLAUR, TLR2, TNF, PLA2G7, IL1R1, MAPK14, IL1RN, TXNRD1, IRF1, MNDA, TLR4, PTGS2, or TNFRSF1A; 
 ii) MMP9, ELA2, SERPINA1, IFI16, TLR2, MAPK14, ALOX5, EGR1, or SERPINE1; or 
 iii) SERPINA1, EGR1, ELA2, IFI16, ALOX5, IL1R1, MAPK14, ICAM1, or TIMP1. 
   c) Table 3 and is selected from:
 i) EGR1, RB1, CDKN1A, NOTCH2, BRAF, BRCA1, TNF, TGFBI, IFITM1, RHOA, NFKB1, NME4, THBS1, SMAD4, TIMP1, ITGB1, TP53, CDK2, ICAM1, PTEN, E2F1, CDK5, TNFRSF6, SOCS1, SRC, MMP9, PLAUR, VEGF, NRAS, SERPINE1, IL1B, CDC25A, VHL, SEMA4D, FOS, AKT1, BCL2, ABL1, RHOC, IL18, G1P3, SKI, TNFRSF1A, CFLAR, or PTCH1; 
 ii) E2F1, BRAF, EGR1, MMP9, SERPINE1, IFITM1, SOCS1, NME4, THBS1, PTEN, BRCA1, RB1, CDKN1A, TIMP1, FOS, NOTCH2, TGFBI, RHOA, CDC25A, CFLAR, PLAUR, TNFRSF6, SEMA4D, or NRAS; or 
 iii) EGR1, BRAF, RB1, E2F1, IFITM1, SOCS1, BRCA1, CDKN1A, NME4, PTEN, MMP9, NOTCH2, THBS1, SERPINE1, TGFB1, TIMP1, RHOA, SMAD4, NFKB1, SEMA4D, ITGB1, TNFRSF6, PLAUR, ICAM1, CDK2, CFLAR, CDC25A, TNFRSF1A, IL18, or CDK5; or 
   d) Table 4 and is selected from:
 i) EGR1, ALOX5, EP300, SMAD3, MAPK1, TGFB1, CREBBP, NFKB1, TOPBP1, EGR2, ICAM1, THBS1, TP53, TNFRSF6, PTEN, PDGFA, SRC, PLAU, FOS, EGR3, NAB1, CEBPB, or CCND2; 
 ii) ALOX5, SERPINE1, EP300, EGR1, MAPK1, PDGFA, THBS1, PTEN, PLAU, CREBBP, FOS, TGFBI, or TNFRSF6; or 
 iii) ALOX5, EP300, EGR1, MAPK1, CREBBP, PTEN, PDGFA, THBS1, SERPINE1, TGFB1, PLAU, TOPBP1, NFKB1, TNFRSF6, ICAM1, or SMAD3. 
   
     
     
         6 . The method of  claim 1 , comprising measuring at least two constituents from:
 a) Table 1, wherein the first constituent is selected from the group consisting of:
 i) ABCC1, ACPP, ADAMTS1, AOC3, AR, BCAM, BCL2, CAV2, CD44, CD48, CD59, CDH1, COL6A2, COVA1, CTNNA1, E2F5, EGR1, EPAS1, G6PD, HSPA1A, IGF1R, KAI1, LGALS8, MEIS1, MUC1, NCOA4, NRP1, PLAU, POV1, PTGS2, PYCARD, SERPINE1, SERPING1, SMARCD3, SORBS1, SOX4, ST14, STAT3, SVIL, and TP53; 
 ii) ABCC1, ACPP, ADAMTS1, AOC3, AR, BCAM, BCL2, BIRC5, CAV2, CD44, CD48, CD59, CDH1, COL6A2, COVA1, CTNNA1, E2F5, EGR1, EPAS1, FGF2, G6PD, GSTT1, HMGA1, HSPA1A, IGF1R, IL8, KRT5, LGALS8, MEIS1, MYC, NCOA4, NRP1, PLAU, POV1, PTGS2, SERPINE1, SERPING1, SORBS1, SOX4, STAT3, SVIL, and TGFB1; and 
 iii) ABCC1, ACPP, ADAMTS1, AOC3, AR, BCAM, BCL2, BIRC5, CAV2, CD44, CD48, CD59, CDH1, COL6A2, COVA1, CTNNA1, E2F5, EGR1, EPAS1, FGF2, G6PD, HMGA1, HSPA1A, IGF1R, IL8, KAI1, KRT5, LGALS8, MEIS1, MUC1, MYC, NCOA4, NRP1, PLAU, POV1, PTGS2, PYCARD, SERPINE1, SERPING1, SMARCD3, SORBS1, SOX4, STAT3, SVIL, TGFB1, and TP53; 
 and the second constituent is any other constituent selected from Table 1, wherein the constituent is selected so that measurement of the constituent distinguishes between a normal subject and a prostate cancer-diagnosed subject in a reference population with at least 75% accuracy; 
   b) Table 2, wherein the first constituent is selected from the group consisting of:
 i) ADAM17, ALOX5, APAF1, C1QA, CASP1, CASP3, CCL3, CCL5, CCR5, CD19, CD4, CD86, CD8A, CXCL1, DPP4, EGR1, ELA2, HLADRA, HMGB1, HMOX1, HSPA1A, ICAM1, IF16, IL10, IL15, IL18, IL18BP, IL1B, IL1R1, IL1RN, IL23A, IL32, IL5, IRF1, MAPK14, MHC2TA, MIF, MMP9, MNDA, MYC, NFKB1, PLA2G7, PLAUR, PTPRC, SERPINA1, SERPINE1, and TNF; 
 ii) ADAM17, ALOX5, APAF1, C1QA, CASP1, CASP3, CCL3, CCL5, CCR3, CCR5, CD19, CD4, CD86, CD8A, CTLA4, CXCL1, CXCR3, DPP4, EGR1, ELA2, HLADRA, HMGB1, HMOX1, HSPA1A, ICAM1, IFI16, IL10, IL15, IL18BP, IL1B, IL1R1, IL1RN, IL23A, IL32, IL5, IL8, IRF1, LTA, MAPK14, MHC2TA, MIF, MMP12, MNDA, MYC, NFKB1, PLA2G7, PLAUR, PTGS2, PTPRC, SERPINA1, SERPINE1, SSI3, TGFB1, TIMP1, TLR2, TLR4, and TNFSF5; and 
 iii) ADAM17, ALOX5, APAF1, C1QA, CASP1, CCL3, CCL5, CCR3, CCR5, CD19, CD4, CD86, CD8A, CTLA4, CXCL1, CXCR3, DPP4, EGR1, ELA2, HLADRA, HMGB1, HMOX1, HSPA1A, ICAM1, IFI16, IL15, IL18, IL18BP, IL1B, IL1R1, IL1RN, IL23A, IL32, IL5, IL8, IRF1, LTA, MAPK14, MHC2TA, MIF, MMP9, MNDA, MYC, NFKB1, PLA2G7, PLAUR, PTGS2, PTPRC, SERPINA1, SERPINE1, TGFB1, TIMP1, TNFSF5, and TOSO; 
 and the second constituent is any other constituent selected from Table 2, wherein the constituent is selected so that measurement of the constituent distinguishes between a normal subject and a prostate cancer-diagnosed subject in a reference population with at least 75% accuracy; 
   c) Table 3 wherein the first constituent is selected from the group consisting of:
 i) ABL1, ABL2, AKT1, ANGPT1, APAF1, ATM, BAD, BAX, BCL2, BRAF, BRCA1, CASP8, CCNE1, CDC25A, CDK2, CDK4, CDK5, CDKN1A, CDKN2A, CFLAR, E2F1, EGR1, ERBB2, FOS, G1P3, GZMA, HRAS, ICAM1, IFITM1, IFNG, IGFBP3, IL18, IL1B, IL8, ITGA1, ITGA3, ITGAE, ITGB1, JUN, MMP9, MSH2, MYC, MYCL1, NFKB1, NME1, NME4, NOTCH2, NRAS, PCNA, PLAUR, PTCH1, PTEN, RAF1, RB1, RHOA, RHOC, SEMA4D, SERPINE1, SKI, SKIL, SMAD4, SOCS1, SRC, TGFBI, THBS1, TIMP1, TNF, TNFRSF10A, TNFRSF6, TP53, and VEGF; 
 ii) ABL1, ABL2, AKT1, ANGPT1, APAF1, ATM, BAD, BAX, BCL2, BRAF, BRCA1, CASP8, CCNE1, CDC25A, CDK2, CDK4, CDK5, CDKN1A, CDKN2A, CFLAR, E2F1, EGR1, ERBB2, FGFR2, FOS, G1P3, GZMA, HRAS, ICAM1, IFITM1, IFNG, IGFBP3, IL18, IL1B, IL8, ITGA1, ITGA3, ITGAE, ITGB1, JUN, MMP9, MSH2, MYC, MYCL1, NFKB1, NME1, NME4, NOTCH2, NRAS, PCNA, PLAUR, PTCH1, PTEN, RAF1, RB1, RHOA, RHOC, S100A4, SEMA4D, SERPINE1, SKI, SKIL, SMAD4, SOCS1, SRC, TGFBI, THBS1, TIMP1, TNFRSF10A, TNFRSF10B, TNFRSF1A, and TNFRSF6; and 
 iii) ABL1, ABL2, AKT1, ANGPT1, APAF1, ATM, BAD, BAX, BCL2, BRAF, BRCA1, CASP8, CCNE1, CDC25A, CDK2, CDK4, CDK5, CDKN1A, CDKN2A, CFLAR, E2F1, EGR1, ERBB2, FGFR2, FOS, G1P3, GZMA, HRAS, ICAM1, IFITM1, IFNG, IGFBP3, IL18, IL1B, IL8, ITGA1, ITGA3, ITGAE, ITGB1, JUN, MMP9, MSH2, MYC, MYCL1, NFKB1, NME1, NME4, NOTCH2, NRAS, PCNA, PLAUR, PTCH1, PTEN, RAF1, RB1, RHOA, RHOC, S100A4, SEMA4D, SERPINE1, SKI, SKIL, SMAD4, SOCS1, SRC, TGFB1, THBS1, TIMP1, TNFRSF10A, TNFRSF10B, TNFRSF1A, TNFRSF6, and VEGF; 
 and the second constituent is any other constituent selected from Table 3, wherein the constituent is selected so that measurement of the constituent distinguishes between a normal subject and a prostate cancer-diagnosed subject in a reference population with at least 75% accuracy; or 
   d) Table 4 wherein the first constituent is selected from the group consisting of:
 i) ALOX5, CCND2, CEBPB, CREBBP, EGR1, EGR2, EGR3, EP300, FOS, ICAM1, JUN, MAP2K1, MAPK1, NAB1, NAB2, NFATC2, NFKB1, NR4A2, PDGFA, PLAU, PTEN, RAF1, S100A6, SERPINE1, SMAD3, SRC, THBS1, and TNFRSF6 
 ii) ALOX5, CCND2, CDKN2D, CEBPB, CREBBP, EGR1, EGR2, EGR3, EP300, FOS, ICAM1, JUN, MAP2K1, MAPK1, NAB1, NAB2, NFATC2, NFKB1, NR4A2, PDGFA, PLAU, PTEN, RAF1, S100A6, SERPINE1, SMAD3, SRC, TGFBI, THBS1, and TOPBP1; and 
 iii) ALOX5, CCND2, CDKN2D, CEBPB, CREBBP, EGR1, EGR2, EGR3, EP300, FOS, ICAM1, JUN, MAP2K1, MAPK1, NAB1, NAB2, NFATC2, NFKB1, NR4A2, PDGFA, PLAU, PTEN, RAFT, S100A6, SERPINE1, SMAD3, SRC, TGFB1, THBS1, and TOPBP1; 
 and the second constituent is any other constituent selected from Table 4, wherein the constituent is selected so that measurement of the constituent distinguishes between a normal subject and a prostate cancer-diagnosed subject in a reference population with at least 75% accuracy; and 
   
     
     
         7 . The method of  claim 1 , wherein the combination of constituents are selected according to any of the models enumerated in Tables 1A, 2A, 3A, or 4A. 
     
     
         8 . The method of  claim 1 , wherein said reference value is an index value. 
     
     
         9 . The method of  claim 2 , wherein said therapy is immunotherapy. 
     
     
         10 . The method of  claim 9 , wherein said constituent is selected from the group constituent is selected from Table 5. 
     
     
         11 . The method of  claim 2 , wherein when the baseline data set is derived from a normal subject a similarity in the subject data set and the baseline date set indicates that said therapy is efficacious. 
     
     
         12 . The method of  claim 2 , wherein when the baseline data set is derived from a subject known to have prostate cancer a similarity in the subject data set and the baseline date set indicates that said therapy is not efficacious. 
     
     
         13 . The method of  claim 1 , wherein expression of said constituent in said subject is increased compared to expression of said constituent in a normal reference sample. 
     
     
         14 . The method of  claim 1 , wherein expression of said constituent in said subject is decreased compared to expression of said constituent in a normal reference sample. 
     
     
         15 . The method of  claim 1 , wherein the sample is selected from the group consisting of blood, a blood fraction, a body fluid, a cells and a tissue. 
     
     
         16 . The method of  claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than ten percent. 
     
     
         17 . The method of  claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than five percent. 
     
     
         18 . The method of  claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than three percent. 
     
     
         19 . The method of  claim 1 , wherein efficiencies of amplification for all constituents are substantially similar. 
     
     
         20 . The method of  claim 1 , wherein the efficiency of amplification for all constituents is within ten percent. 
     
     
         21 . The method of  claim 1 , wherein the efficiency of amplification for all constituents is within five percent. 
     
     
         22 . The method of  claim 1 , wherein the efficiency of amplification for all constituents is within three percent. 
     
     
         23 . A kit for detecting prostate cancer in a subject, comprising at least one reagent for the detection or quantification of any constituent measured according to  claim 1  and instructions for using the kit.